All Trials

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with mCRPC who have progressed on at least one next‑generation hormonal agent and 1–2 taxane regimens (ECOG 0–1) are randomized to the CYP11A1 inhibitor opevesostat (with physiologic steroid replacement) versus switching to abiraterone/prednisone or enzalutamide; efficacy will be evaluated separately in AR ligand‑binding domain mutation–positive and –negative cohorts. Prior PARP inhibitor or 177Lu‑PSMA‑617 is allowed; key exclusions include significant cardiovascular, thromboembolic, seizure, or endocrine risks and drug–drug interactions.

ClinicalTrials.gov ID: NCT06136624

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with extensive-stage SCLC who have not progressed after induction platinum–etoposide plus durvalumab and have adequate tissue for central subtyping (A/N/I/P) and SLFN11 testing are randomized to durvalumab maintenance alone versus durvalumab plus a biomarker-directed agent: PARP1 inhibitor saruparib for subtype P or SLFN11+ A/N; ATR inhibitor ceralasertib for SLFN11– A/N; or NKG2A inhibitor monalizumab for subtype I. Treated, stable brain metastases allowed; leptomeningeal disease excluded.

ClinicalTrials.gov ID: NCT06769126

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with untreated unresectable locally advanced or metastatic urothelial carcinoma with a qualifying FGFR3 genetic alteration (ECOG 0–2, measurable disease) are randomized to add oral vepugratinib (highly FGFR3-selective kinase inhibitor) versus oral placebo to first-line enfortumab vedotin (nectin-4–directed ADC) plus pembrolizumab (anti–PD-1). Key exclusions include prior systemic therapy for advanced/metastatic disease, baseline grade ≥2 neuropathy, uncontrolled/untreated CNS disease, and certain corneal/retinal disorders.

ClinicalTrials.gov ID: NCT07218380

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (including ER-low/HER2-negative) whose tumors are PD-L1–negative or otherwise ineligible for standard PD-(L)1 inhibitor plus chemotherapy receive physician’s choice chemotherapy (paclitaxel/nab-paclitaxel, gemcitabine/carboplatin, or eribulin). Patients are randomized double-blind to add pumitamig (BNT327), a bispecific anti–PD-L1/anti–VEGF-A antibody (checkpoint blockade plus anti-angiogenic therapy), versus placebo.

ClinicalTrials.gov ID: NCT07173751

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic HR+/HER2− (including HER-low) breast cancer harboring an activating PIK3CA mutation, with measurable disease or evaluable bone-only disease and no prior systemic therapy for advanced disease (including endocrine-sensitive or endocrine-resistant relapse strata; ovarian/GnRH suppression required when applicable). Randomized double-blind comparison of oral LY4064809 (STX-478/tersolisib), a mutant-selective allosteric PI3Kα inhibitor, plus palbociclib and investigator-choice endocrine therapy (AI or fulvestrant) versus placebo with the same backbone, continued until progression or toxicity.

ClinicalTrials.gov ID: NCT07174336

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults (women or men) with ER+, HER2− unresectable locally advanced or metastatic breast cancer who are systemic-therapy naïve for advanced disease (de novo or recurrence >12 months after adjuvant endocrine therapy; ECOG 0–1; measurable or bone-only disease; premenopausal women/men require GnRH suppression) are randomized to palazestrant (OP-1250; oral complete ER antagonist/next-generation SERD that promotes ER degradation, including in ESR1-mutant tumors) plus ribociclib versus standard letrozole plus ribociclib in the first-line setting.

ClinicalTrials.gov ID: NCT07085767

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PD-L1 CPS ≥1 persistent/recurrent or newly metastatic cervical squamous/adenocarcinoma/adenosquamous carcinoma (ECOG 0–1) who complete standard first-line induction pembrolizumab + paclitaxel + platinum (with optional bevacizumab) without progression are randomized in maintenance to sacituzumab tirumotecan (MK-2870; TROP2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload) plus pembrolizumab versus pembrolizumab alone, with bevacizumab allowed in either arm. The study tests whether adding MK-2870 improves PFS and OS and further characterizes safety/tolerability of the combination.

ClinicalTrials.gov ID: NCT07216703

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolls adults with previously untreated metastatic (stage IV) colorectal adenocarcinoma, ECOG 0–1, RECIST-measurable disease, adequate organ function, excluding MSI-high/dMMR or BRAF V600E tumors and patients with active symptomatic CNS metastases, significant bleeding/cardiovascular risk, or active autoimmune disease requiring systemic therapy. Compares PF-08634404 (SSGJ-707), a bispecific antibody targeting PD-1 and VEGF, plus standard first-line IV chemotherapy versus bevacizumab (anti-VEGF) plus the same chemotherapy, treating until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT07222800

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, unresectable or metastatic colorectal adenocarcinoma with measurable disease that is MSS/pMMR and without known BRAF V600E are randomized (blinded) to first-line doublet chemotherapy (FOLFOX/FOLFIRI ± CAPOX) plus pumitamig (BNT327/PM8002), a bispecific anti–PD-L1/anti–VEGF-A antibody, versus the same chemotherapy plus bevacizumab. Primary efficacy focuses on objective response in the dose-selection portion and progression-free survival by blinded central review in the confirmatory portion.

ClinicalTrials.gov ID: NCT07221357

A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with previously untreated, locally advanced unresectable or metastatic colorectal cancer that is non–MSI-H/dMMR and centrally confirmed PD-L1–positive (ECOG 0–1; excludes BRAF V600E and prior checkpoint inhibitor use). Patients are randomized to mFOLFOX6 plus bevacizumab alone or the same backbone plus nivolumab with oral ONO-4578 (two dose levels), a prostaglandin E2 EP4 (PTGER4) receptor antagonist intended to reduce PGE2-driven tumor immunosuppression and enhance PD-1 blockade.

ClinicalTrials.gov ID: NCT06948448